Prevalence of Cervical Intraepithelial Lesions and Associated Factors Among Women Attending a Cervical Cancer Clinic in Western Uganda; Results Based on Pap Smear Cytology

Overview

Journal SAGE Open Med

Publisher Sage Publications

Specialty General Medicine

Date 2024 May 20

PMID 38764539

Authors

Frank Ssedyabane

Nixon Niyonzima

Josephine Nambi Najjuma

Abraham Birungi

Raymond Atwine

Deusdedit Tusubira

Thomas C Randall

Cesar M Castro

Hakho Lee

Joseph Ngonzi

Affiliations

Soon will be listed here.

Abstract

Introduction: There are high incidence and mortality rates of cervical cancer among females in East Africa. This is exacerbated by limited up-to-date data on premalignant lesions and associated factors in this setting. In this study, we determined the prevalence of cervical intraepithelial lesions and associated factors among women attending the Mbarara Regional Referral Hospital cervical cancer clinic in Southwestern Uganda.

Methods: In this cross-sectional study, 364 participants were recruited from among women attending the Mbarara Regional Referral Hospital cervical cancer clinic from 1 April to 30 June 2023. On consent, the study nurse collected demographic data and Pap smears, which were microscopically examined and reported by a laboratory scientist and a pathologist following the Bethesda grading system (2014). Statistical analyses were done in STATA version 17, using proportions, Chi-square, bivariate, and multivariate logistic regression analysis to determine associated factors at ⩽0.05 significance level.

Results: The mean age of participants was 41.9 years. A third of all study participants (37.6%, 132/351) were contraceptive users, mostly hormonal contraceptives (87.1%, 115/132). Almost 88% (307/351) had an unknown Human Papilloma Virus status. The prevalence of cervical intraepithelial lesions among our study participants was 6.6% (23/351), of which 73.9% (17/23) were low-grade squamous intraepithelial lesions. More than half (9/17, 52.9%) of low-grade squamous intraepithelial lesions were active hormonal contraceptive users. Use of hormonal contraceptives (OR: 3.032, : 0.0253), use of intrauterine devices (OR: 6.284, : 0.039), and any family history of cervical cancer (OR: 4.144, : 0.049) were significantly associated with cervical intraepithelial lesions.

Conclusion: The prevalence of cervical intraepithelial lesions was 6.6%, lower than global estimates. Use of hormonal and intrauterine device contraceptives, as well as family history of cervical cancer, were significantly associated with cervical intraepithelial lesions among our study population. Prospective studies are recommended to further understand associations between different types of intrauterine devices and hormonal contraceptives, and cervical lesions.

References

Castellsague X, Pawlita M, Roura E, Margall N, Waterboer T, Bosch F . Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort. Int J Cancer. 2013; 135(2):440-52. DOI: 10.1002/ijc.28665. View

Pyeon D, Pearce S, Lank S, Ahlquist P, Lambert P . Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 2009; 5(2):e1000318. PMC: 2642596. DOI: 10.1371/journal.ppat.1000318. View

Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. View

Shimakawa Y, Bah E, Wild C, Hall A . Evaluation of data quality at the Gambia national cancer registry. Int J Cancer. 2012; 132(3):658-65. DOI: 10.1002/ijc.27646. View

Bhatla N, Puri K, Joseph E, Kriplani A, Iyer V, Sreenivas V . Association of Chlamydia trachomatis infection with human papillomavirus (HPV) & cervical intraepithelial neoplasia - a pilot study. Indian J Med Res. 2013; 137(3):533-9. PMC: 3705662. View

Malande O, Munube D, Afaayo R, Annet K, Bodo B, Bakainaga A . Barriers to effective uptake and provision of immunization in a rural district in Uganda. PLoS One. 2019; 14(2):e0212270. PMC: 6375600. DOI: 10.1371/journal.pone.0212270. View

Agita A, Alsagaff M . Inflammation, Immunity, and Hypertension. Acta Med Indones. 2017; 49(2):158-165. View

Gedefaw A, Astatkie A, Tessema G . The prevalence of precancerous cervical cancer lesion among HIV-infected women in southern Ethiopia: a cross-sectional study. PLoS One. 2013; 8(12):e84519. PMC: 3869839. DOI: 10.1371/journal.pone.0084519. View

Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A . Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007; 370(9599):1609-21. DOI: 10.1016/S0140-6736(07)61684-5. View

10.

Maglennon G, McIntosh P, Doorbar J . Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology. 2011; 414(2):153-63. PMC: 3101335. DOI: 10.1016/j.virol.2011.03.019. View

11.

Stelzle D, Tanaka L, Lee K, Ibrahim Khalil A, Baussano I, Shah A . Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2020; 9(2):e161-e169. PMC: 7815633. DOI: 10.1016/S2214-109X(20)30459-9. View

12.

Jolly P, Mthethwa-Hleta S, Padilla L, Pettis J, Winston S, Akinyemiju T . Screening, prevalence, and risk factors for cervical lesions among HIV positive and HIV negative women in Swaziland. BMC Public Health. 2017; 17(1):218. PMC: 5320649. DOI: 10.1186/s12889-017-4120-3. View

13.

Yuan Y, Cai X, Shen F, Ma F . HPV post-infection microenvironment and cervical cancer. Cancer Lett. 2020; 497:243-254. DOI: 10.1016/j.canlet.2020.10.034. View

14.

Zondervan K, Carpenter L, Painter R, Vessey M . Oral contraceptives and cervical cancer--further findings from the Oxford Family Planning Association contraceptive study. Br J Cancer. 1996; 73(10):1291-7. PMC: 2074516. DOI: 10.1038/bjc.1996.247. View

15.

Louie K, de Sanjose S, Diaz M, Castellsague X, Herrero R, Meijer C . Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer. 2009; 100(7):1191-7. PMC: 2670004. DOI: 10.1038/sj.bjc.6604974. View

16.

Bhaskaran K, Douglas I, Forbes H, Dos-Santos-Silva I, Leon D, Smeeth L . Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014; 384(9945):755-65. PMC: 4151483. DOI: 10.1016/S0140-6736(14)60892-8. View

17.

Buskwofie A, David-West G, Clare C . A Review of Cervical Cancer: Incidence and Disparities. J Natl Med Assoc. 2020; 112(2):229-232. DOI: 10.1016/j.jnma.2020.03.002. View

18.

Assoumou S, Ndjoyi Mbiguino A, Mabika B, Nguizi Ogoula S, El Mzibri M, Khattabi A . Human papillomavirus genotypes distribution among Gabonese women with normal cytology and cervical abnormalities. Infect Agent Cancer. 2016; 11:2. PMC: 4714494. DOI: 10.1186/s13027-016-0046-0. View

19.

Jensen K, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer S . Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer. 2012; 108(1):234-9. PMC: 3553518. DOI: 10.1038/bjc.2012.513. View

20.

Akinyemiju T . Socio-economic and health access determinants of breast and cervical cancer screening in low-income countries: analysis of the World Health Survey. PLoS One. 2012; 7(11):e48834. PMC: 3498259. DOI: 10.1371/journal.pone.0048834. View